Clinical trials
mCRC clinical trials
Below are recruiting mcrc clinical trials, each written for real people, not researchers. We’re tracking 38 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06678919Recruiting
A registry for metastatic colorectal cancer beyond second line
This study tracks people with metastatic colorectal cancer who have already tried at least two standard treatments. It aims to collect real-world data on how well newer treatments work in later lines of therapy.
LinzAges 18 years+ - NCT06922383RecruitingPhase 1/Phase 2
Study of arfolitixorin in advanced colorectal cancer
This study tests a new drug called arfolitixorin given with standard chemotherapy (FOLFOX or FOLFIRI) plus a targeted therapy for people with advanced colorectal cancer that has spread. It may help the chemotherapy work better.
BerlinAges 18 years+ - NCT05768503RecruitingPhase 3
Test new drugs after colorectal cancer chemotherapy
This Phase 3 trial compares a new treatment combination (chidamide plus sintilimab plus bevacizumab) versus the standard second-line chemotherapy (FOLFIRI plus bevacizumab) for advanced colorectal cancer that is microsatellite stable/low. It aims to see which treatment works better and is safer for people whose cancer grew after first-line oxaliplatin-based therapy.
Hefei, AnhuiAges 18–75 - NCT07724223RecruitingPhase 2
Combination targeted therapy for advanced colorectal cancer
This trial tests a combination of two targeted drugs (fruquintinib and a drug that targets EGFR) as a third-line treatment for people with a specific type of colorectal cancer that has not responded to previous therapies. It may offer a new option for patients whose tumors are 'wild-type' for certain genes.
Beijing, Beijing MunicipalityAges 18–75 - NCT04547166RecruitingPhase 2/Phase 3
New targeted immune drug plus bevacizumab and chemo for colon cancer
This trial studies serplulimab (an immune-related drug) together with bevacizumab and chemotherapy to treat metastatic colorectal (colon) cancer that cannot be removed with surgery. It aims to see whether this combination improves outcomes and is safe.
Guangzhou, GuangdongAges 18–75 - NCT05967143Recruiting
Registry study for first-time SIR-Spheres in liver tumors
This is an observational (real-world) study that follows people with certain unresectable liver tumors who are getting SIR-Spheres for the first time. It helps doctors understand how this treatment is used in routine care and what outcomes patients experience.
Clichy, CedexAges 18 years+ - NCT06749015Recruiting
Study for BRAFV600E Mutant Metastatic Colorectal Cancer
This trial tests a treatment for people whose colorectal cancer has spread and cannot be removed by surgery, and who have a specific gene change called BRAFV600E. It aims to find out if the treatment can help shrink or control the cancer.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT07463599RecruitingPhase 1/Phase 2
Tegavivint for advanced colorectal cancer after other treatments
This early-phase trial tests an experimental drug called tegavivint for people with advanced colorectal cancer who have already tried several standard treatments. It aims to see if the drug can shrink or slow the growth of tumors.
Scottsdale, ArizonaAges 18 years+ - NCT06643793RecruitingPhase 2
Irinotecan liposome combo for advanced colorectal cancer
This trial tests a new form of the chemotherapy drug irinotecan (called irinotecan liposome) combined with two other chemo drugs and a targeted therapy (bevacizumab) for people with advanced colorectal cancer that has already been treated with oxaliplatin. The goal is to see if this combination can shrink tumors or slow the cancer's growth.
Nanjing, JiangsuAges 18–75 - NCT07446322RecruitingPhase 2
Study of a new drug plus standard chemo for advanced colorectal cancer
This trial tests if adding the experimental drug pelareorep to standard chemotherapy (FOLFIRI) and bevacizumab can help people with a specific type of advanced colorectal cancer that has a RAS mutation and is not caused by high microsatellite instability. You may be able to join if you've already tried one type of chemotherapy and it stopped working or you couldn't tolerate it.
Homewood, AlabamaAges 18 years+ - NCT07441369Enrolling by invitationPhase 2
Abemaciclib with chemotherapy for advanced colorectal liver metastases
This trial tests combining the targeted drug abemaciclib with standard chemotherapy (FOLFOX or FOLFIRI) for people whose colorectal cancer has spread to the liver and cannot be removed surgically. It may be an option if you've already tried two or three prior treatments without success.
ShanghaiAges 18–75 - NCT07416552RecruitingPhase 1
Study of CEA-PRIT 2.0 for advanced colorectal cancer
This trial tests an experimental drug called CEA-PRIT 2.0 in people whose colorectal cancer has spread and is no longer responding to standard treatments. The goal is to see if it can help shrink tumors or slow the cancer's growth.
Chicago, IllinoisAges 18 years+ - NCT06826092RecruitingPhase 2
Metformin for advanced colorectal cancer with chemotherapy
This trial tests whether adding metformin (a diabetes drug) to standard chemotherapy (FOLFIRI) and targeted therapy can help people with metastatic colorectal cancer live longer or respond better to treatment.
Kaohsiung CityAges 20–90 - NCT06829355RecruitingPhase 2
Thymalfasin plus triple therapy for advanced colorectal cancer
This trial tests a combination of three drugs plus thymalfasin, an immune-boosting medicine, for people whose advanced colorectal cancer has not responded to at least two prior treatments. It's designed specifically for the common type of colorectal cancer (pMMR/MSS) to see if adding this immune therapy can help.
Beijing, ChinaAges 18–75 - NCT07389265RecruitingPhase 3
Continuing cetuximab after first treatment stops working for metastatic colorectal cancer
This trial tests if continuing the targeted therapy cetuximab after initial treatment stops working can help people with advanced colorectal cancer. Participants have a specific gene profile (RAS and BRAF normal) and their cancer responds well at first.
AnconaAges 18 years+ - NCT07334587Enrolling by invitation
Comparing two chemotherapies for advanced colorectal cancer
This trial compares two chemotherapy drug combinations (FOLFOX-6 and CAPOX) to see which works better and has fewer side effects for people with colorectal cancer that has spread. It may help you and your doctor choose the best treatment option.
Lahore, Punjab ProvinceAges 20–70 - NCT07244705RecruitingPhase 1/Phase 2
Study of ABT-301 plus tislelizumab and bevacizumab for advanced colorectal cancer
This trial tests a new drug combination (ABT-301, tislelizumab, and bevacizumab) for people with a specific type of advanced colorectal cancer that has not responded to at least two prior treatments. It aims to see if this combination can help shrink tumors or slow the disease.
Liverpool, New South WalesAges 18 years+ - NCT07224724Recruiting
Exosome liquid biopsy for colorectal cancer spread
This study uses a blood test to detect if colorectal cancer that has spread to the liver has also spread to other parts of the body. It may help doctors better understand how the cancer is moving and guide treatment decisions.
Duarte, CaliforniaAges 18 years+ - NCT07224841Recruiting
Blood test to predict targeted therapy response in colorectal cancer
This study is developing a blood test that looks at DNA signals to see if certain targeted therapies will work for people with metastatic colorectal cancer. It may help doctors choose the right treatment in the future.
Duarte, CaliforniaAges 18 years+ - NCT06621173RecruitingEarly Phase 1
Gene therapy for advanced colorectal cancer (dMMR/MSI-H)
This trial tests a new gene therapy (HNF4α SrRNA) given through a vein for people with advanced colorectal cancer that has a specific genetic marker (dMMR or MSI-H). It's for those who have already tried standard treatments without success or couldn't take them.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT07171554Recruiting
A test to find the best drugs for advanced colorectal cancer
This trial uses a special test to help choose which drugs might work best for you if you have metastatic colorectal cancer that has stopped responding to first treatment. The goal is to match you with a more effective next therapy.
Lørenskog, AkershusAges 18 years+ - NCT06949982RecruitingPhase 2
Comparing two treatments for advanced colorectal cancer with RAS mutations
This trial tests if a combination of hydroxychloroquine, methotrexate, capecitabine, and bevacizumab works better than regorafenib for people with metastatic colorectal cancer that has a RAS gene mutation and has stopped responding to at least two prior treatments.
Saint Petersburg, Sankt-PeterburgAges 18 years+ - NCT07085169RecruitingPhase 2
Low-dose chemo combo for advanced colorectal cancer
This trial tests a lower dose of a chemotherapy pill (trifluridine/tipiracil) combined with bevacizumab for advanced colorectal cancer that has not responded to at least two prior treatments. The goal is to see if this combination can help control the cancer with fewer side effects.
SanmingAges 60 years+ - NCT07035886Recruiting
Fruzaqla for metastatic colorectal cancer in South Korea
This study monitors the safety and effectiveness of Fruzaqla (a targeted therapy taken as a pill) in adults with advanced colorectal cancer that has spread to other parts of the body. It is being done in South Korea to gather real-world information about how well the treatment works and how patients respond.
SeoulAges 18 years+
Hear when a new mCRC trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for mcrc?
- Yes. Clin2 currently lists 38 recruiting mcrc studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a mcrc trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a mcrc trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.